Clinical pharmacokinetics and pharmacodynamics of G3139 (Genta Incorporated) antisense oligonucleotide targeting BCL-2.

被引：0

作者：

Fingert, HJ ^{[1
]}

Klem, RE ^{[1
]}

机构：

[1] Genta Inc, Lexington, MA USA

来源：

CLINICAL CANCER RESEARCH | 1999年 / 5卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

585

引用

页码：3847S / 3848S

页数：2

共 50 条

[1] Clinical development of G3139 antisense drug (oligonucleotide) targeting BCL-2
Fingert, H
EUROPEAN JOURNAL OF CANCER, 1999, 35 : S34 - S34
[2] G 3139: Augmerosen, Bcl-2 antisense oligonucleotide - Genta, GC 3139, Genasense
不详
Drugs in R & D, 2002, 3 (1) : 44 - 49
[3] Oblimersen: Augmerosen, BCL-2 antisense oligonucleotide - Genta, G 3139, GC 3139, oblimersen sodium
不详
Drugs in R & D, 2007, 8 (5) : 321 - 334
[4] Modulation of tumor radiation response with G3139, a bcl-2 antisense oligonucleotide
Nicole Wiedenmann
Masashi Koto
Uma Raju
Luka Milas
Kathryn A. Mason
Investigational New Drugs, 2007, 25 : 411 - 416
[5] Modulation of tumor radiation response with G3139, a bcl-2 antisense oligonucleotide
Wiedenmann, Nicole
Koto, Masashi
Raju, Uma
Milas, Luka
Mason, Kathryn A.
INVESTIGATIONAL NEW DRUGS, 2007, 25 (05) : 411 - 416
[6] In vitro/in vivo response of EBV-associated lymphoproliferative disease to bcl-2 antisense oligonucleotide (G3139 from Genta, Inc.).
Lacy, J
Guinness, ME
Kenney, JL
BLOOD, 1999, 94 (10) : 386A - 386A
[7] Results of a phase 1 clinical trial of BCL-2 antisense molecule G3139 (Genta) in patients with non-Hodgkin's lymphoma (NHL).
Waters, JS
Webb, A
Cunningham, D
Clarke, PA
di Stefano, F
Raynaud, F
Brown, BD
Cotter, F
BRITISH JOURNAL OF CANCER, 1999, 80 : 62 - 62
[8] G3139, a Bcl-2 antisense oligodeoxynucleotide, induces clinical responses in VAD refractory myeloma
van de Donk, NWCJ
de Weerdt, O
Veth, G
Eurelings, M
van Stralen, E
Frankel, SR
Hagenbeek, A
Bloem, AC
Lokhorst, HM
LEUKEMIA, 2004, 18 (06) : 1078 - 1084
[9] Pharmacokinetics of Bcl-2 antisense oligonucleotide (G3139) combined with doxorubicin in SCID mice bearing human breast cancer solid tumor xenografts
Daniel E. Lopes de Menezes
Lawrence D. Mayer
Cancer Chemotherapy and Pharmacology, 2002, 49 : 57 - 68
[10] Pharmacokinetics of Bcl-2 antisense oligonucleotide (G3139) combined with doxorubicin in SCID mice bearing human breast cancer solid tumor xenografts
de Menezes, DEL
Mayer, LD
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2002, 49 (01) : 57 - 68

← 1 2 3 4 5 →